Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9309320
SERIAL NO

12521625

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITAETSKLINIKUM HEIDELBERGIM NEUENHELMER FELD 672 69120 HEIDLEBERG
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTSHEIDELBERG

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Herold-Mende, Christel Bammental, DE 7 15
Kleber, Susanne Heidelberg, DE 5 10
Krammer, Peter G Heidelberg, DE 2 10
Martin-Villalba, Ana Heidelberg, DE 7 12
Sancho-Martinez, Ignacio Heidelberg, DE 8 24
Wiestler, Benedikt Schriesheim, DE 2 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 12, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00